Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
IN8bio, Inc. is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for cancer and autoimmune diseases. Its proprietary DeltEx platform enables ex vivo expansion, genetic engineering, and scalable manufacturing of allogeneic, autologous, and iPSC-derived T cells. The company focuses on innovative immunotherapies, including T cell engagers, targeting solid and hematologic cancers to improve patient outcomes and achieve durable remissions.
This description was generated via AI from an annual report. Updated about 1 year ago.